Plain-English translation of NCT07108855 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing indocyanine green, a fluorescent dye that can be seen with special near-infrared cameras, to help doctors better visualize the exact boundaries and depth of early-stage cancers in the esophagus or stomach during a minimally invasive removal procedure. The goal is to help doctors ensure they remove all of the cancer tissue, which could reduce the chance of the cancer coming back.
Current cancer removal techniques work well at taking out the visible tumor, but doctors sometimes miss the deepest parts of the cancer or its edges, leading to recurrence. This medication may provide better visualization to help doctors identify exactly where the cancer ends so they can remove it completely.
You likely qualify if…
You likely don't qualify if…
You will receive an injection of the fluorescent dye about 30 minutes before your scheduled endoscopic cancer removal procedure. During the procedure, your doctor will use a special camera that detects the dye to better visualize your tumor's boundaries and depth, helping guide complete cancer removal. The study involves 10 participants total and is designed to test whether this approach is safe and helpful.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Netherlands